Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 21, 2026Journal of Pharmacology and Pharmacotherapeutics

Simvastatin Mediated Suppression of Epithelial-Mesenchymal Transition: A Potential Therapeutic Strategy for Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

NSNimisha SabuRRRajesh RamachandranCRC.S. Rejiya

Discussion

Loading...

Member takes

Overview

Randomized trial investigates simvastatin's effects on EMT and cell behavior in breast cancer, suggesting a new therapeutic avenue.

Key Points

  • This study aims to evaluate the effects of simvastatin on suppressing epithelial-mesenchymal transition in breast cancer cells.
  • MCF-7 cells were treated with simvastatin to assess anti-proliferative and pro-apoptotic effects using various assays.
  • EMT-related activities were measured via cell migration and aggregation assays, along with β-catenin activity analysis.
  • Gene expression changes in response to simvastatin were evaluated using reverse transcriptase polymerase chain reaction.
  • Simvastatin induced dose-dependent cytotoxicity, leading to significant morphological changes associated with apoptosis.
  • There was a marked reduction in cell migration and aggregation in simvastatin-treated MCF-7 cells.
  • β-catenin activity and gene expression related to EMT were downregulated following treatment with simvastatin.

Cite This Study

Sabu et al. (2026) studied this question.

synapsesocial.com/papers/6a5f0bea86a4235cc161981ahttps://doi.org/10.1177/0976500x261461099
View Full Paper
Ask AI
Bookmark
Share